Matthew Lowrie, quality assurance manager, Almac Clinical Technologies explores how the evolving regulatory guidance around data integrity is impacting clinical trial applications and data.
Zabir Macci, director of eCOA business strategy & sales engineering at IQVIA, describes how to navigate global regulatory guidance for successful multinational clinical trials.
Q&A with Kimberly Remillard, RAC, senior regulatory affairs manager at Thermo Fisher Scientific, examines how leveraging the power of Pharma 4.0 can ensure data integrity within biopharma.
Bruno Speder, VP of regulatory affairs & consultancy services, hVIVO, discusses how Human Challenge Trials (HCT) can be used in the framework of expedited review programs as part of drug and vaccine development.
Christian Merup, CEO of Wellma, explains the winning recipe for successful co-manufacturers in Europe, including the underlying threads and unique capabilities of the leaders in the current CDMO market.
Nick Porter, World Courier, and Chris Williams, Alloga Europe, discuss the heightened demand for cold chain and cryogenic storage to support advanced therapy medicinal products (ATMPs) and the solutions needed to safeguard the supply chain.
A new report published by Connect in Pharma highlights a range of forces shaping the future of the pharmaceutical manufacturing and drug-delivery fields, from machine learning and connected devices to eco-friendly strategies.
Amin Sikander, Synkrato co-founder & president, examines the trends within pharma manufacturing that will incur as its processes become smarter, more data-driven and transparent.
Editor, Rebekah Jordan, reviews pharma's transformation to digital solutions, and how the industry will need to navigate the associated risks to prevent breaches in security and safety.
Last Thursday, chancellor Jeremy Hunt announced new measures for smoother medicine approvals in the UK, increased support for R&D, and a simplified tax system for SMEs. UK biotech company, Nevrargenics shared its position on the 2023 Budget.
Editor, Rebekah Jordan, sat with Mark Bagnall, CEO of Phenomix Sciences, to understand how the company is redefining the way obesity disease is treated with precision medicine to allow for better treatment decisions and patient outcomes.
